OptiNose (OPTN)
(Real Time Quote from BATS)
$1.12 USD
+0.08 (7.69%)
Updated May 9, 2024 02:53 PM ET
2-Buy of 5 2
D Value A Growth F Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
OPTN 1.12 +0.08(7.69%)
Will OPTN be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for OPTN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for OPTN
Will Gain Therapeutics, Inc. (GANX) Report Negative Q1 Earnings? What You Should Know
Will OptiNose (OPTN) Report Negative Q1 Earnings? What You Should Know
OPTN: What are Zacks experts saying now?
Zacks Private Portfolio Services
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
MEI Pharma, Inc. (MEIP) Reports Q2 Loss, Misses Revenue Estimates
Other News for OPTN
Lake Street Reaffirms Their Buy Rating on Optinose (OPTN)
DTCK, NCI and SLNH among pre-market losers
Optinose sees FY24 XHANCE net revenue at $85M-$95M
Optinose announces $55M registered direct offering at $1.00 per share
Optinose Announces $55 Million Registered Direct Offering